Composition: Each film‑coated tablet contains Empagliflozin 25 mg and Linagliptin 5 mg.

Indication: Used as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.

Pharmacology:

Empagliflozin is an SGLT2 inhibitor that lowers blood glucose by increasing urinary glucose excretion.
Linagliptin is a DPP‑4 inhibitor that increases incretin hormones (GLP‑1 and GIP), stimulating insulin release and reducing glucagon levels. Together, they help maintain better blood sugar control.

Dosage & Administration: Take as directed by your physician. Swallow whole with water; do not crush or chew. Can be taken with or without food.

Side Effects:

Precautions: